Start › Niedrobnokomórkowy rak płuca › Karolina Północna › Durham
Badania kliniczne dla Niedrobnokomórkowy rak płuca w mieście Durham, NC
39 badań dla Niedrobnokomórkowy rak płuca szuka uczestników w ośrodkach w mieście Durham i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekrutacjaFaza 3
- Duke University Medical Center, Durham
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekrutacjaFaza 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi dalej
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #12, Durham
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RekrutacjaFaza 3
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill · 10 mi dalej
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekrutacjaFaza 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RekrutacjaFaza 3
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekrutacjaFaza 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi dalej
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RekrutacjaFaza 3
- Duke University Medical Center, Durham
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RekrutacjaFaza 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi dalej
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RekrutacjaFaza 1/2
- Duke Cancer Center Durham, Durham
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekrutacjaFaza 3
- Clinical Study Site, Durham
- Clinical Study Site, Chapel Hill · 10 mi dalej
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
RekrutacjaFaza 3
- Durham VA Health Care System, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekrutacjaFaza 1/2
- Duke University School of Medicine, Durham
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekrutacjaFaza 2/3
- Duke University Medical Center, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
RekrutacjaFaza 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mi dalej
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekrutacjaBadanie obserwacyjne
- UNC- Chapel Hill, Chapel Hill · 10 mi dalej
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekrutacjaFaza 1
- Duke Cancer Institute, Durham
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekrutacjaFaza 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi dalej
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RekrutacjaFaza 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10 mi dalej
- University of North Carolina, Chapel Hill · 10 mi dalej
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekrutacjaFaza 1/2
- Duke Cancer Institute, Durham
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RekrutacjaFaza 2
- UNC Health - University of North Carolina, Chapel Hill · 10 mi dalej
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekrutacjaFaza 1
- Duke University Medical Center, Durham
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RekrutacjaFaza 1/2
- Duke Cancer Institute, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- Duke Cancer Center, Durham
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RekrutacjaFaza 2
- University of North Carolina, Chapel Hill · 10 mi dalej
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekrutacjaFaza 1
- Duke Cancer Institute /ID# 276267, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RekrutacjaFaza 1
- Research Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekrutacjaFaza 1
- Duke Cancer Center /ID# 251975, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekrutacjaFaza 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekrutacjaFaza 1
- Duke Cancer Center, Durham
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekrutacjaFaza 2/3
- Durham VA Medical Center, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Rekrutacja
- Durham VA Medical Center, Durham, NC, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
RekrutacjaWczesna faza 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi dalej
GEMINI-NSCLC: NSCLC Biomarker Study
RekrutacjaBadanie obserwacyjne
- Duke University, Durham
- UNC, Chapel Hill · 10 mi dalej
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi dalej
A Study of NX-1607 in Adults With Advanced Malignancies
RekrutacjaFaza 1
- University of North Carolina, Chapel Hill · 10 mi dalej
Badania dla Niedrobnokomórkowy rak płuca w innych miastach
- Houston, TX145 badań
- New York City, NY121 badań
- Arlington, VA104 badań
- Nashville, TN97 badań
- Boston, MA90 badań
- Los Angeles, CA87 badań
- St. Louis, MO73 badań
- Chicago, IL61 badań
- Baltimore, MD60 badań
- San Antonio, TX59 badań
- Columbus, OH57 badań
- Washington, DC55 badań
Inne badania w mieście Durham
- Rak piersi64 badań
- Nowotwory (wszystkie typy)58 badań
- Szpiczak mnogi37 badań
- Ostra białaczka szpikowa33 badań
- Nowotwór przerzutowy33 badań
- Rak prostaty32 badań
- Rak płuc32 badań
- Rak jelita grubego i odbytnicy28 badań
- Rak jajnika27 badań
- Przewlekła białaczka limfocytowa27 badań
- Niewydolność serca26 badań
- Rak trzustki24 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.